ReviewFrontiers in psychiatry2020
Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder.
Review in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 76 citations in OpenAlex.
- Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026Review
- Sex-related neuropsychiatric recovery from maternal perinatal depression and expression of monoamine and amino acid neurotransmitter levels in specific brain regions of adult offspring.Scientific reports · 2026Article
- Sigma receptor ligands in selected affective disorders, psychoses, and addictions - a narrative review.Pharmacological reports : PR · 2026Review
- Ginsenosides in the management of depression: a comprehensive pharmacological review.Chinese medicine · 2026Review
- Neuroprotective potential of selenium nanoparticles and/or physical and mental activities against social isolation-induced depression in a rat model: inflammatory, oxidative stress, apoptotic, and neurotransmission modulatory pathways.Frontiers in pharmacology · 2026Article
- The dual functions of Ziziphi spinosae semen as medicine and food: origins, cross-domain applications, antidepressant metabolites, and pharmacological mechanisms.Frontiers in pharmacology · 2026Review
- Bridging reward and resilience: the endocannabinoid system as a unifying mechanism in exercise-induced protection against major depressive disorder.Frontiers in psychiatry · 2026Review
- Article
- Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin.International journal of molecular sciences · 2025Review
- Botulinum Toxin: An Unconventional Tool for the Treatment of Depression?Brain sciences · 2025Review
- Mapping cross-modal functional connectivity of major neurotransmitter systems in the human brain.Brain structure & function · 2025Article
- Ghrelin in Depression: A Promising Therapeutic Target.Molecular neurobiology · 2025Review
- Advancing depression treatment: the role of sigma receptor ligands.Frontiers in neuroscience · 2025Review
- Network-based mapping and neurotransmitter architecture of brain gray matter correlates of extraversion.Frontiers in systems neuroscience · 2025Article
- Positioning berries in nutritional psychiatry: potential for prevention and co-therapy in mental health.Frontiers in behavioral neuroscience · 2025Article
- Novel therapeutic targets for major depressive disorder related to oxidative stress identified by integrative multi-omics and multi-trait study.Translational psychiatry · 2024Article
- Potential Plausible Role of Stem Cell for Treating Depressive Disorder: a Retrospective Review.Molecular neurobiology · 2024Review
- Differences in Children and Adolescents with Depression before and after a Remediation Program: An Event-Related Potential Study.Brain sciences · 2024Article
- Mechanistic interplay of different mediators involved in mediating the anti-depressant effect of isoflavones.Metabolic brain disease · 2024Review
- Obesity mediates the relationship between depression and infertility: insights from the NHANES 2013-2018 cross-sectional study and a Mendelian randomization study.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a complex psychiatric disease requiring multidisciplinary approaches to identify specific risk factors and establish more efficacious treatment strategies. Although the etiology and pathophysiology of MDD are not clear until these days, it is acknowledged that they are almost certainly multifactorial and comprehensive. Monoamine neurotransmitter system dysfunction and specific personality traits are independent risk factors for depression and suicide. These factors also demonstrate complex interactions that influence MDD pathogenesis and symptom expression. In this review, we assess these relationships with the aim of providing a reference for the development of precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.